These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

927 related articles for article (PubMed ID: 37389876)

  • 21. Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.
    Qin K; Honjo K; Sherrill-Mix S; Liu W; Stoltz RM; Oman AK; Hall LA; Li R; Sterrett S; Frederick ER; Lancaster JR; Narkhede M; Mehta A; Ogunsile FJ; Patel RB; Ketas TJ; Cruz Portillo VM; Cupo A; Larimer BM; Bansal A; Goepfert PA; Hahn BH; Davis RS
    PLoS Med; 2023 Jun; 20(6):e1004157. PubMed ID: 37384638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response.
    Takamatsu Y; Omata K; Shimizu Y; Kinoshita-Iwamoto N; Terada M; Suzuki T; Morioka S; Uemura Y; Ohmagari N; Maeda K; Mitsuya H
    Microbiol Spectr; 2022 Dec; 10(6):e0271622. PubMed ID: 36219096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.
    Merid Y; Tekleselasie W; Tesfaye E; Gadisa A; Fentahun D; Abate A; Alemu A; Mihret A; Mulu A; Gelanew T
    Front Immunol; 2023; 14():1163688. PubMed ID: 37398668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
    Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
    Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence and Protective Potential of SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home Cohort.
    Smoot K; Yang J; Tacker DH; Welch S; Khodaverdi M; Kimble W; Wen S; Amjad A; Marsh C; Perrotta PL; Hodder S
    JAMA Netw Open; 2022 Sep; 5(9):e2231334. PubMed ID: 36098966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2.
    Nickel O; Rockstroh A; Wolf J; Landgraf S; Kalbitz S; Kellner N; Borte M; Pietsch C; Fertey J; Lübbert C; Ulbert S; Borte S
    PLoS One; 2022; 17(10):e0263861. PubMed ID: 36256664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Broad Cross-reactive IgA and IgG Against Human Coronaviruses in Milk Induced by COVID-19 Vaccination and Infection.
    Wang J; Young BE; Li D; Seppo AE; Zhou Q; Wiltse A; Nowak-Wegrzyn A; Murphy K; Widrick K; Diaz N; Cruz-Vasquez J; Järvinen KM; Zand MS
    medRxiv; 2022 Mar; ():. PubMed ID: 35313594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection.
    Abela IA; Schwarzmüller M; Ulyte A; Radtke T; Haile SR; Ammann P; Raineri A; Rueegg S; Epp S; Berger C; Böni J; Manrique A; Audigé A; Huber M; Schreiber PW; Scheier T; Fehr J; Weber J; Rusert P; Günthard HF; Kouyos RD; Puhan MA; Kriemler S; Trkola A; Pasin C
    mBio; 2024 Feb; 15(2):e0272223. PubMed ID: 38270455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan.
    Kubota-Koketsu R; Terada Y; Yunoki M; Sasaki T; Nakayama EE; Kamitani W; Shioda T
    Transfusion; 2021 Feb; 61(2):356-360. PubMed ID: 33104267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine.
    Kobashi Y; Shimazu Y; Kawamura T; Nishikawa Y; Omata F; Kaneko Y; Kodama T; Tsubokura M
    PLoS One; 2022; 17(6):e0269917. PubMed ID: 35687563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers.
    Moncunill G; Aguilar R; Ribes M; Ortega N; Rubio R; Salmerón G; Molina MJ; Vidal M; Barrios D; Mitchell RA; Jiménez A; Castellana C; Hernández-Luis P; Rodó P; Méndez S; Llupià A; Puyol L; Rodrigo Melero N; Carolis C; Mayor A; Izquierdo L; Varela P; Trilla A; Vilella A; Barroso S; Angulo A; Engel P; Tortajada M; García-Basteiro AL; Dobaño C
    EBioMedicine; 2022 Jan; 75():103805. PubMed ID: 35032961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses.
    Lawrenz J; Xie Q; Zech F; Weil T; Seidel A; Krnavek D; van der Hoek L; Münch J; Müller JA; Kirchhoff F
    Clin Infect Dis; 2022 Aug; 75(1):e653-e661. PubMed ID: 35079775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike.
    Crowley AR; Natarajan H; Hederman AP; Bobak CA; Weiner JA; Wieland-Alter W; Lee J; Bloch EM; Tobian AAR; Redd AD; Blankson JN; Wolf D; Goetghebuer T; Marchant A; Connor RI; Wright PF; Ackerman ME
    Elife; 2022 Mar; 11():. PubMed ID: 35289271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diverse Humoral Immune Responses in Younger and Older Adult COVID-19 Patients.
    Sasson JM; Campo JJ; Carpenter RM; Young MK; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Teng AA; Pablo JV; Liang X; Yee A; Petri WA; Camerini D
    mBio; 2021 Jun; 12(3):e0122921. PubMed ID: 34182775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term course of neutralising antibodies against SARS-CoV-2 in vaccinated and unvaccinated staff and residents in a Swiss nursing home: a cohort study 2021-2022.
    Perrig L; Abela IA; Banholzer N; Audigé A; Epp S; Mugglin C; Zürcher K; Egger M; Trkola A; Fenner L
    Swiss Med Wkly; 2023 Dec; 153():3502. PubMed ID: 38579325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization.
    Wang J; Guo C; Cai L; Liao C; Yi H; Li Q; Hu H; Deng Q; Lu Y; Guo Z; Chen Z; Lu J
    Front Immunol; 2021; 12():772511. PubMed ID: 34868035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals.
    Ruggiero A; Piubelli C; Calciano L; Accordini S; Valenti MT; Carbonare LD; Siracusano G; Temperton N; Tiberti N; Longoni SS; Pizzato M; Accordini S; ; Fantoni T; Lopalco L; Beretta A; Bisoffi Z; Zipeto D
    EBioMedicine; 2022 Mar; 77():103888. PubMed ID: 35196644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
    Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
    Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China.
    Wu F; Liu M; Wang A; Lu L; Wang Q; Gu C; Chen J; Wu Y; Xia S; Ling Y; Zhang Y; Xun J; Zhang R; Xie Y; Jiang S; Zhu T; Lu H; Wen Y; Huang J
    JAMA Intern Med; 2020 Oct; 180(10):1356-1362. PubMed ID: 32808970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.